Skip to main content
Clinical Trials/NCT02912221
NCT02912221
Completed
N/A

Influence of Increased Physical Activity on Patient Reported Measures of Disease Activity in Inflammatory Arthritis

University of Pennsylvania1 site in 1 country71 target enrollmentApril 24, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Arthritis, Psoriatic
Sponsor
University of Pennsylvania
Enrollment
71
Locations
1
Primary Endpoint
Percentage of Days Goal Met
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study will examine the benefits of a monitored physical activity program for participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) using a wearable activity device (e.g.fitbit). The goals of this pilot study are to examine 1) whether an incentive is better than no incentive in maintaining an increased level of physical activity and 2) the benefits of physical activity on patient reported disease activity in inflammatory arthritis.

Detailed Description

Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic, systemic inflammatory disorders affecting 1-2% of the US population. Ongoing chronic inflammation and lack of exercise due to arthritis are each associated with pain, fatigue, depression, muscle loss, obesity, and development of chronic diseases such as cardiovascular disease and diabetes, all of which impact physical functioning and quality of life. Increases in physical activity can significantly impact each one of these outcomes and are likely to positively impact a patients experience of their disease. This study will examine the benefits of a monitored physical activity program. This study will use a wearable activity device (e.g. fitbit) to monitor step counts and will incentivize one group to achieve higher step counts than the control group. The primary goal of this pilot study will be to determine whether one incentive (loss aversion) is better than no incentive in increasing step counts and maintaining an increased level of physical activity. Additional outcomes of interest are patient reported disease activity (using the RAPID3 patient reported outcome) and physician measured disease activity, quality of life assessments and weight loss.

Registry
clinicaltrials.gov
Start Date
April 24, 2017
End Date
November 24, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • A diagnosis of RA or PsA by a rheumatologist
  • Followed by a Penn rheumatologist
  • Age 18-80
  • A RAPID3 score of 3
  • An active email account
  • Owns a smart phone and able to download an application
  • Willing to take internet based surveys weekly and allow data from a smart phone application to be uploaded

Exclusion Criteria

  • Inability to walk or regular use of a wheel chair or assistive device (e.g., walker or cane)
  • Hospitalization within the past 30 days
  • Heart or lung disease that precludes participation in an exercise study

Outcomes

Primary Outcomes

Percentage of Days Goal Met

Time Frame: 12 Weeks

The primary outcome will be percent of days meeting goal during the intervention period

Secondary Outcomes

  • RAPID3(26 Weeks)
  • Psoriasis(26 Weeks)
  • Patient Feedback(14 Weeks and 26 Weeks)
  • Sleep Disturbance and Fatigue(26 Weeks)
  • Completion of Activities by Study Participants (Feasibility)(26 Weeks)

Study Sites (1)

Loading locations...

Similar Trials